ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2011
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Bridging the gap - Establishing a dental-oncology service in a cancer centre.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study.Bone reports · 2024Article
- Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients.Bone reports · 2021Article
- Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey.Journal of bone oncology · 2021Article
- Practical update for the use of bone-targeted agents in patients with bone metastases from metastatic breast cancer or castration-resistant prostate cancer.Current oncology (Toronto, Ont.) · 2020Article
- Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).Journal of bone oncology · 2020Article
- Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis.Cancer management and research · 2018Article
- Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis.Oncotarget · 2017Article
- Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS).Journal of bone oncology · 2016Review
- Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.Journal of bone oncology · 2015Article
- Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers.Journal of bone oncology · 2013Article
- Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.Journal of bone oncology · 2013Article
- The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment.Journal of clinical medicine · 2013Review
- Zoledronic acid in genitourinary cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Review
- A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.Journal of bone oncology · 2013Review
- Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases.Journal of clinical medicine · 2013Review
- De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.Journal of bone oncology · 2013Article
- Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.Current oncology (Toronto, Ont.) · 2012Article
- Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer?Current oncology (Toronto, Ont.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastases can be associated with a significant worsening of patient morbidity and mortality. Bisphosphonates have been extensively researched and shown to delay the onset and reduce the incidence of complications from bone metastases. The most commonly used bisphosphonates are intravenous pamidronate, intravenous ibandronate, intravenous zoledronic acid and oral/intravenous clodronate. Several bone-targeted agents with innovative mechanisms of action are currently being developed. These include receptor activator of nuclear factor-kB ligand (RANKL) inhibitors, CCR1 inhibitors, Src inhibitors, DKK1-neutralising antibodies, activin antagonists and endothelin-1 inhibitors. In an era of individualised medicine, oncologists are being faced with an increasing number of questions when dealing with bone-targeted agents. These questions not only include the choice of which drug to use (i.e. bisphosphonates or RANKL inhibitor) but also the best treatment strategy to use. This review will provide medical oncologists with a practical guide to the use of bone-targeted agents.
Indexed as
Identifiers
21785900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.